Etirinotecan Pegol

Tumor

Nektar TherapeuticsOtherPhase 2Dormant

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

928 Active assets in the Tumor cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Vinorelbine Shi Yanxia	Phase 3	BB
Inno-206 The First Affiliated Hospital of Soochow University	Phase 2/3	BB
DINITROGEN MONOXIDE Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Etirinotecan Pegol is also rated in:

metastatic neoplasmDormant

BB

Indicative ·

69 / 100

breast carcinomaDormant

BB

Indicative ·

64 / 100

small cell lung carcinomaDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.